Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 17/20 | 0.57 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.48 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25515284 | 1.00 | TLR2 (0.57) | TLR2LPAR1LPAR3 | |
| SCHEMBL18057124 | 1.00 | TLR2 (0.57) | TLR2LPAR1LPAR3 | |
| SCHEMBL18057125 | 1.00 | TLR2 (0.57) | TLR2LPAR1LPAR3 | |
| SCHEMBL11304197 | 1.00 | TLR2 (0.57) | TLR2LPAR1LPAR3 | |
| SCHEMBL15149390 | 0.92 | TLR2 (0.53) | TLR2LPAR1LPAR3 | |
| SCHEMBL102391 | 0.91 | TLR2 (0.56) | TLR2LPAR1LPAR3 | |
| SCHEMBL14950501 | 0.91 | TLR2 (0.58) | TLR2LPAR1LPAR3 | |
| SCHEMBL14924385 | 0.90 | TLR2 (0.57) | TLR2LPAR1LPAR3 | |
| SCHEMBL16475661 | 0.90 | TLR2 (0.46) | TLR2 | |
| SCHEMBL15071438 | 0.90 | TLR2 (0.57) | TLR2LPAR1LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240065982-A1 | LIPID NANOPARTICLES FOR DELIVERING THERAPEUTICS TO LUNGS | GENEVANT SCIENCES GMBH (CH) | 2024-02-29 | — | — | US | disclosed |
| US-20240065982-A1 | LIPID NANOPARTICLES FOR DELIVERING THERAPEUTICS TO LUNGS | GENEVANT SCIENCES GMBH (CH) | 2024-02-29 | — | — | US | disclosed |
| WO-2023144798-A1 | IONIZABLE CATIONIC LIPIDS FOR LIPID NANOPARTICLES | GENEVANT SCIENCES GMBH (CH) | 2023-08-03 | — | — | WO | disclosed |
| US-20230212578-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERTRIGLYCERIDEMIA | ARBUTUS BIOPHARMA CORPORATION (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230212578-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERTRIGLYCERIDEMIA | ARBUTUS BIOPHARMA CORPORATION (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230165973-A1 | COMPOSITIONS AND METHODS FOR DELIVERING MESSENGER RNA | ARBUTUS BIOPHARMA CORPORATION (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230150926-A1 | CATIONIC LIPIDS FOR LIPID NANOPARTICLE DELIVERY OF THERAPEUTICS TO HEPATIC STELLATE CELLS | GENEVANT SCIENCES GMBH (CH) | 2023-05-18 | — | — | US | disclosed |
| US-20230139594-A1 | CATIONIC LIPIDS FOR LIPID NANOPARTICLE DELIVERY OF THERAPEUTICS TO HEPATIC STELLATE CELLS | GENEVANT SCIENCES GMBH (CH) | 2023-05-04 | — | — | US | disclosed |
| US-20230139594-A1 | CATIONIC LIPIDS FOR LIPID NANOPARTICLE DELIVERY OF THERAPEUTICS TO HEPATIC STELLATE CELLS | GENEVANT SCIENCES GMBH (CH) | 2023-05-04 | — | — | US | disclosed |
| US-20180208932-A1 | COMPOSITIONS AND METHODS FOR SILENCING HEPATITIS B VIRUS GENE EXPRESSION | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-07-26 | — | — | US | disclosed |
| US-20140065228-A1 | NOVEL LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2014-03-06 | — | — | US | disclosed |
| US-20140065228-A1 | NOVEL LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2014-03-06 | — | — | US | disclosed |
| US-8492359-B2 | Lipid formulations for nucleic acid delivery | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2013-07-23 | — | — | US | disclosed |
| US-8492359-B2 | Lipid formulations for nucleic acid delivery | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2013-07-23 | — | — | US | disclosed |
| US-20130116307-A1 | NOVEL CYCLIC CATIONIC LIPIDS AND METHODS OF USE | PROTIVA BIOTHERAPEUTICS INC. (CA) | 2013-05-09 | — | — | US | disclosed |
| US-20130064894-A1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2013-03-14 | — | — | US | disclosed |
| US-20120183581-A1 | NOVEL LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY | PROTIVA BIOTHERAPEUTICS, INC (CA) | 2012-07-19 | — | — | US | disclosed |
| US-8058069-B2 | Lipid formulations for nucleic acid delivery | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-11-15 | — | — | US | disclosed |
| US-20110178155-A1 | SILENCING OF CSN5 GENE EXPRESSION USING INTERFERING RNA | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-07-21 | — | — | US | disclosed |
| US-20100130588-A1 | NOVEL LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116307-A1 | NOVEL CYCLIC CATIONIC LIPIDS AND METHODS OF USE | LDLR, CETP, ABHD16A | TLR2 1612/4885LPAR1 26/4885LPAR3 12/4885 |
| US-20180208932-A1 | COMPOSITIONS AND METHODS FOR SILENCING HEPATITIS B VIRUS GENE EXPRESSION | HAVCR2, HDGF, LDLR | TLR2 1160/4885LPAR1 66/4885LPAR3 64/4885 |
| US-20110178155-A1 | SILENCING OF CSN5 GENE EXPRESSION USING INTERFERING RNA | CUL5, CSNK2A1, CSNK2A3 | TLR2 3872/4885LPAR1 657/4885LPAR3 333/4885 |
| US-20230139594-A1 | CATIONIC LIPIDS FOR LIPID NANOPARTICLE DELIVERY OF THERAPEUTICS TO HEPATIC STELLATE CELLS | LIPC, SGMS2, LPCAT3 | TLR2 666/4885LPAR1 33/4885LPAR3 15/4885 |
| US-20130064894-A1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | PLIN3, CETP, LDLR | TLR2 1362/4885LPAR1 68/4885LPAR3 34/4885 |
| US-20120183581-A1 | NOVEL LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY | SARNP, NPC1L1, SNRPE | TLR2 2508/4885LPAR1 23/4885LPAR3 36/4885 |
| US-20240065982-A1 | LIPID NANOPARTICLES FOR DELIVERING THERAPEUTICS TO LUNGS | LPAR6, LIPA, LPCAT1 | TLR2 578/4885LPAR1 8/4885LPAR3 5/4885 |
| US-20230150926-A1 | CATIONIC LIPIDS FOR LIPID NANOPARTICLE DELIVERY OF THERAPEUTICS TO HEPATIC STELLATE CELLS | LIPC, SGMS2, LPCAT3 | TLR2 666/4885LPAR1 33/4885LPAR3 15/4885 |
| US-20100130588-A1 | NOVEL LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY | SARNP, NPC1L1, SNRPE | TLR2 2508/4885LPAR1 23/4885LPAR3 36/4885 |
| US-20230212578-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERTRIGLYCERIDEMIA | APOB, APOL1, LPL | TLR2 4001/4885LPAR1 452/4885LPAR3 74/4885 |
| US-20230165973-A1 | COMPOSITIONS AND METHODS FOR DELIVERING MESSENGER RNA | NSUN3, CETP, SYNCRIP | TLR2 1133/4885LPAR1 115/4885LPAR3 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.